nach oben

Drugs

Erschienen in:

01.05.2008 | Adis Drug Profile

Mosapride

In Gastrointestinal Disorders

verfasst von: Monique P. Curran, Dean M. Robinson

Erschienen in: Drugs | Ausgabe 7/2008

Einloggen, um Zugang zu erhalten

Abstract

▴ Mosapride was effective in improving overall symptoms in patients with gastrointestinal disorders, including chronic gastritis, gastro-oesophageal reflux disease and functional dyspepsia.
▴ Mosapride was more effective than teprenone in improving gastric stasis symptoms and gastric pain after 2 weeks of therapy (p < 0.001) in an open-label trial in 1042 patients with functional dyspepsia.
▴ Mosapride was as effective as famotidine and itopride, but more effective than tandospirone, in improving overall or individual symptoms of functional dyspepsia in randomized trials. However, in one randomized, double-blind trial in patients with mild to severe disease, the improvement in overall symptoms of functional dyspepsia did not differ significantly between mosapride or placebo treatment.
▴ Mosapride was well tolerated, with diarrhoea/loose stools, dry mouth, malaise and headache being reported in <5% of patients.

The use of trade names is for product identification purposes only and does not imply endorsement.

Mizuta Y, Shikuwa S, Isomoto H, et al. Recent insights into digestive motility in functional dyspepsia. J Gastroenterol 2006 Nov;41(11): 1025–40PubMedCrossRef

Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999 Sep; 45 Suppl. 2: II43–7PubMedCrossRef

Grundy D, AL-Chaer ED, Aziz Q, et al. Fundamentals of neurogastroenterology: basic science. Gastroenterology 2006; 130(5): 1391–411PubMedCrossRef

Makimoto N, Sukurai-Yamashita Y, Furuichi A, et al. In vivo assessment of acceleration of motor activity associated with acetylcholine release via 5-hydroxytriptamine. Jpn J Pharmacol 2002; 90: 28–35PubMedCrossRef

Carlsson L, Amos GJ, Andersson B, et al. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J Pharmacol Exp Ther 1997 Jul; 282(1): 220–7PubMed

Toga T, Kohmura Y, Kawatsu R. The 5-HT4 agonists cisapride, mosapride, and CJ-033466, a novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities. J Pharmacol Sci 2007 Oct; 105(2): 207–10PubMedCrossRef

Potet F, Bouyssou T, Escande D. Gastrointestinal prokinetic drugs have a different affinity for the human cardiac human ether-à-gogo K+ channel. J Pharmacol Exp Ther 2001; 289(3): 1007–12

Yoshida N, Kato S, Ito T. Mosapride citrate: gastroprokinetic. Drugs Future 1993; 18(6): 513–5

Karasawa T, Yoshida N, Furukawa K, et al. Comparison of gastrokinetic effects of AS-4370, cisapride and BRL 24924. Eur J Pharmacol 1990 Jul 6; 183: 2181CrossRef

10.

Yoshida N, Omoya H, Furukawa K, et al. Pharmacological studies on mosapride citrate (AS-4370), a gastroprokinetic agent (1): comparison with cisapride and metoclopramide [in Japanese]. Jpn Pharmacol Ther 1993; 21(9): 249–64

11.

Yoshida N, Omoya H, Oka M, et al. AS-4370, a novel gastrokinetic agent free of dopamine D₂ receptor antagonist properties. Arch Int Pharmacodyn Ther 1989; 300: 51–67PubMed

12.

Yoshida N, Omoya H, Kato S, et al. Pharmaocological effects of the new gastroprokinetic agent mosapride citrate and its metabolite in experimental animals. Arzneimittelforschung 1993; 43(10): 1078–83PubMed

13.

Hamelin B, Bredberg E, Röhss K, et al. Effects of mosapride on oesophageal motility in humans [abstract no. A51]. Dig Dis Sci 1996 Sep; 41(9): 1892

14.

Mitsufuji S, Nakao H, Taniguchi J, et al. Effect of mosapride citrate on esophageal motility in healthy subjects and patients with gastroesophageal reflux disease [in Japanese]. Prog Med 2002; 22(3): 801–5

15.

Ruth M, Finizia C, Cange L, et al. The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2003 Oct; 15(10): 1115–21PubMedCrossRef

16.

Cho YK, Choi M-G, Han HW, et al. The effect of mosapride on esophageal motility and bolus transit in asymptomatic volunteers. J Clin Gastroenterol 2006 Apr; 40(4): 286–92PubMedCrossRef

17.

Kanaizumi T, Nakano H, Matsui Y, et al. Prokinetic effect of AS-4370 on gastric emptying in healthy adults. Eur J Clin Pharmacol 1991; 41(4): 335–7PubMedCrossRef

18.

Suyama T, Tokubayashi F, Omatsu Y, et al. Accelerating effect of AS-4370 (mosapride) on gastric emptying time (double sampling test method) and its clinical efficacy on chronic gastritis accompanied by epigastric symptoms [in Japanese]. Jpn Arch Intern Med 1993; 40(7): 175–83

19.

Wei W, Ge Z-Z, Lu H, et al. Effect of mosapride on gastrointestinal transit time and diagnostic yield of capsule endoscopy. J Gastroenterol Hepatol 2007 Oct; 22(10): 1605–8PubMedCrossRef

20.

Asai H, Udaka F, Hirano M, et al. Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson’s disease. Parkinsonism Relat Disord 2005; 11(8): 499–502PubMedCrossRef

21.

Asakawa H, Hayashi I, Fukui T, et al. Effect of mosapride on glycemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy. Diabetes Res Clin Pract 2003; 61(3): 175–82PubMedCrossRef

22.

Yamada M, Hongo M. Effects of prokinetic agents: comparison between AS4370 and EM523L. Gastroenterol Jpn 1993 Dec; 28(6): 836

23.

Inui A, Yoshikawa T, Nagai R, et al. Effects of mosapride citrate, a 5-HT4 receptor agonist, on colonie motilit in conscious guinea pigs. Jpn J Pharmacol 2002; 90: 313–20PubMedCrossRef

24.

Liu Z, Sakakibara R, Odaka T, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 anatgonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005; 20(6): 680–6PubMedCrossRef

25.

Kojima Y, Fujii H, Katsui R, et al. Enhancement of the intrinsic defecation reflex by mosapride, a 5-HT4 agonist, in chronically lumbosacral denervated guinea pigs. J Smooth Muscle Res 2006; 42(5): 139–47PubMedCrossRef

26.

Kojima Y, Nakagawa T, Katsui R, et al. A 5-HT4 agonist, mosapride, enhances intrinsic rectorectal and rectonal reflexes after removal of extrinsic nerves in guinea pigs. Am J Physiol Gastrointest Liver Physiol 2005; 289: G351–60PubMedCrossRef

27.

Ruth M, Hamelin B, Röhss K, et al. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998 Jan; 12(1): 35–40PubMedCrossRef

28.

Itoh H, Nagano T, Takeyama M. Effects of mosapride citrate on human plasma levels of motilin, gastrin, somatostatin, and secretin. Biol Pharm Bull 2001 Sep; 24(9): 1072–5PubMedCrossRef

29.

Hayakawa A, Kawahara K, Ueda Y, et al. Clinical study of AS-4370 in non-ulcer dyspepsia: effects of AS-4370 on upper abdominal symptoms and on hormones [in Japanese]. Rinsho Iyaku 1992; 8(3): 639–45

30.

Kii Y, Ito T. Effects of 5-HT4-receptor agonists, cisapride, mosapride citrate, and zacopride, on cardiac action potentials in guinea pig isolated papillary muscles. J Cardiovasc Pharmacol 1997 May; 29(5): 670–5PubMedCrossRef

31.

Katoh T, Saitoh H, Ohno N, et al. Drug interaction between mosapride and erythromycin without electrocardiographic changes. Jpn Heart J 2003 Mar; 44(2): 225–34PubMedCrossRef

32.

Horii S, Takeda T, Fujimoto Y, et al. Clinical study on safety of mosapride in combination therapy with psychiatric drugs [in Japanese]. Rinsho Iyaku 2000; 16(2): 153–62

33.

Takeuchi Y, Watanabe H, Imawari M. Mosapride citrate, a serotonin HT4 selective agonist, beneficially affects pharmacokinetics of proton pump inhibitor [abstract no. T1693]. Gastroenterology 2005 Apr; 128 (4 Suppl. 2): A–531

34.

Sakashita M, Yamaguchi T, Miyazaki H, et al. Pharmaco-kinetics of the gastrokinetic agent mosapride citrate after single and multiple oral administrations in healthy subjects. Arzneimittelforschung 1993; 43(8): 867–72PubMed

35.

Ogihara T, Higaki J, Azuma J, et al. Pharmacokinetic study of AS-4370 in the elderly: comparison with the young [in Japanese]. Rinsho Iyaku 1994; 10(11): 2489–97

36.

Dainippon Pharmaceutical Co., Ltd. Gasmotin®: mosapride citrate preparation. Prescribing information. Osaka, 2004

37.

Miyoshi A, Yoshida Y, Masamune O, et al. Phase II study of two dosage regimens of AS-4370 tablet: randomised comparison of doses taken before and after meals [in Japanese]. Rinsho Iyaku 1998; 14(6): 1025–36

38.

Misawa T, Okabe H, Chijiiwa Y, et al. Clinical study of AS-4370 on upper abdominal symptoms in chronic gastritis [in Japanese]. Rinsho Iyaku 1993; 9(9): 2167–76

39.

Toyota T, Hongo M, Sato M, et al. Clinical evaluation of mosapride citrate (AS-4370) on dyspepsia symptoms in chronic gastritis [in Japanese]. Rinsho Iyaku 1993; 9(8): 1887–95

40.

Miyoshi A, Miwa T, Harasawa S, et al. Dose-finding study of AS-4370 (mosapride citrate) in patients with chronic gastritis [in Japanese]. Rinsho Iyaku 1998; 14(6): 1069–90

41.

Miyoshi A, Miwa T, Harasawa S, et al. Clinical evaluation of AS-4370 on epigastric symptoms associated with chronic gastritis [in Japanese]. Rinsho Iyaku 1998; 14(6): 1037–53

42.

Miyoshi A, Miwa T, Harasawa S, et al. Dose finding study of AS-4370 in patients with non-ulcer dyspepsia [in Japanese]. Rinsho Iyaku 1990 Nov; 6: 2295–310

43.

Miyoshi A, Sekiguchi T, Miwa T, et al. Clinical assessment of AS-4370 in the treatment of reflux oesophagitis: dose-comparison study by randomization [in Japanese]. Rinsho Iyaku 1993; 9(6): 1327–41

44.

Hongo M. Initial approach and pharmacotherapy for functional dyspepsia: a large clinical trial in Japan [abstract no. T1247, plus poster]. Gastroenterology 2006 Apr; 130 (4 Suppl. 2): 506

45.

Hallerbäck BI, Bommelaer G, Bredberg E, et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther 2002 May; 16(5): 959–67PubMedCrossRef

46.

Kinoshita Y, Hashimoto T, Kawamura A, et al. Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Aliment Pharmacol Ther 2005 Jun; 21 Suppl. 2: 37–41CrossRef

47.

Otaka M, Jin M, Odashima M, et al. New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment Pharmacol Ther 2005 Jun; 21 Suppl. 2: 42–6CrossRef

48.

Seno H, Nakase H, Chiba T. Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. Aliment Pharmacol Ther 2005 Jan 1; 21 Suppl. 2: 32–6CrossRef

49.

Amarapurkar DN, Rane P. Randomised, double-blind, comparative study to evaluate the efficacy and safety of ganaton (itopride hydrochloride) and mosapride citrate in the management of functional dyspepsia. J Indian Med Assoc 2004 Dec; 102(12): 735–7, 760PubMed

50.

Miyoshi A, Sekiguchi T, Harasawa S, et al. Clinical evaluation of mosapride (AS-4370) on gastroesophageal reflux disease: multi-centered double-blind comparative study with cisapride [in Japanese]. Rinsho Iyaku 1998; 14(6): 1055–68

51.

Madan K, Ahuja V, Kashyap PC, et al. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Dis Esophagus 2004; 17(4): 274–8PubMedCrossRef

52.

Kanaizumi T, Nakano H, Kuriya N. Clinical evaluation of AS-4370 in ambulatory patients with epigastric digestive tract disorder after gastric surgery by double-blind study [in Japanese]. Rinsho Iyaku 1992; 8(7): 1559–68

53.

Kanaizumi T, Nakano H. Clinical evaluation of long-term administration of mosapride citrate (AS-4370) in postoperative ambulatory patients with epigastric digestive tract disorders [in Japanese]. Rinsho Iyaku 1993; 9(8): 1879–86

54.

Kanaizumi T, Nakano H, Kuriya N. Clinical evaluation of AS-4370 in hospitalized patients with epigastric symptoms after gastric surgery in a double-blind comparative study [in Japanese]. Rinsho Iyaku 1992; 8(12): 2831–40

55.

Odaka T, Suzuki T, Seza A, et al. Serotonin 5-HT4 receptor agonist (mosapride citrate) [in Japanese]. Nippon Rinsho 2006; 64(8): 1491–4PubMed

56.

Hiyama T, Yoshihara M, Matsuo K, et al. Treatment of functional dyspepsia with serotonin agonists: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2007 Oct; 22(10): 1566–70PubMedCrossRef

57.

Oikawa T, Takemoto Y, Haramu K. Postmarketing surveillance of mosapride citrate (Gasmotin®) in patients with non-ulcer dyspepsia on long-term administration [in Japanese]. Rinsho Iyaku 2005; 21(8): 831–7

58.

Ohki R, Takahashi M, Mizuno O, et al. Torsades de pointes ventricular tachycardia induced by mosapride and flecainide in the presence of hypokalemia. Pacing Clin Electrophysiol 2001 Jan; 24(1): 119–21PubMedCrossRef

59.

Dainippon Pharmaceutical Co. Ltd. Launch of Gasmotin® in South Korea [media release]. Available from URL: http://www.dainippon-pharm.co.jp [Accessed 2008 Mar 14]

60.

Eisai TMCL. Eisai submits application for gastroprokinetic agent Gasmotin® in Thailand [media release]. Available from URL: http://www.eisai.co.jp [Accessed 2008 Jan 17]

61.

Dainippon Sumitomo Pharma Co. Ltd., Eisai Co.. Dainippon Sumitomo Pharma and Eisai signed licensing agreement for Gasmotin®, a gastroprokinetic agent, for countries in Asia including ASEAN members [online]. Available from URL: http://www.ds-pharma.co.jp [Accessed 2008 Jan 17]

Titel: Mosapride
In Gastrointestinal Disorders
verfasst von: Monique P. Curran
Dean M. Robinson
Publikationsdatum: 01.05.2008
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 7/2008
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200868070-00007

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2008

Posaconazole

Renal Disease in Patients with HIV Infection

Drugs in the Newspapers

Capecitabine, Alone and in Combination, in the Management of Patients with Colorectal Cancer

Novel Thrombopoietic Agents

Scientific Rationale for Combination of a Calcium Channel Antagonist and an HMG-CoA Reductase Inhibitor